Pliant Therapeutics (PLRX) Income from Continuing Operations (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Income from Continuing Operations of 57309000.0 for Q1 2026, up 4.32% year-over-year from 54935379.26 in Q1 2025, and down 281.73% quarter-over-quarter from 15013000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Income from Continuing Operations for 8 consecutive years, with 57309000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 4.32% year-over-year to 57309000.0; the TTM figure through Mar 2026 stood at 187657000.0 (up 21.15% YoY), while the FY2025 annual figure was 374505000.0, up 12.27% from the prior year.
- Income from Continuing Operations retreated to 57309000.0 in Q1 2026 per PLRX's latest filing, from 15013000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 15013000.0 in Q4 2025 and bottomed at 86286000.0 in Q2 2025.
- Historically, Income from Continuing Operations has averaged 47600411.76 across 5 years, with a median of 48557000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations tumbled 75.63% — and 2025, when it soared 72.71%.
- Pliant Therapeutics' Income from Continuing Operations stood at 35804000.0 in 2022, then sank by 75.63% to 62882000.0 in 2023, then rose by 12.5% to 55021000.0 in 2024, then jumped by 72.71% to 15013000.0 in 2025, then tumbled by 281.73% to 57309000.0 in 2026.
- Business Quant data shows PLRX's Income from Continuing Operations at 57309000.0 in Q1 2026, 15013000.0 in Q4 2025, and 29049000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | Pliant Therapeutics | 70.59 Mn | 70.59 Mn | - | -22.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.37 Mn |
| Mar 31, 2026 | -57.31 Mn |
| Dec 31, 2025 | -15.01 Mn |
| Sep 30, 2025 | -29.05 Mn |
| Jun 30, 2025 | -86.29 Mn |
| Mar 31, 2025 | -59.90 Mn |
| Dec 31, 2024 | -55.02 Mn |
| Sep 30, 2024 | -61.43 Mn |
| Jun 30, 2024 | -61.64 Mn |
| Mar 31, 2024 | -53.73 Mn |
| Dec 31, 2023 | -62.88 Mn |
| Sep 30, 2023 | -47.67 Mn |
| Jun 30, 2023 | -48.56 Mn |
| Mar 31, 2023 | -41.78 Mn |
| Dec 31, 2022 | -35.80 Mn |
| Sep 30, 2022 | -33.44 Mn |
| Jun 30, 2022 | -30.15 Mn |
| Mar 31, 2022 | -29.56 Mn |
| Dec 31, 2021 | -23.46 Mn |
| Sep 30, 2021 | -27.15 Mn |